Dry Powder Inhaler Containing Treprostinil Gets FDA Approval
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Yutrepia is an inhaled dry powder formulation of tresprostinil delivered through a palm-sized device.
Tyvaso DPI is an investigational drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
Absolute risk reduced by 19 percentage points, with number needed to treat to prevent syncope of 5.3
The approval was based on data from a single sequence cross-over phase 3 study that evaluated the safety, tolerability and pharmacokinetics of temporarily switching between the tablet and IV formulation.
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil.
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension